KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Shares Outstanding (2016 - 2025)

Pacific Biosciences Of California has reported Shares Outstanding over the past 16 years, most recently at $302.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $302.0 million for Q4 2025, up 2.56% from a year ago — trailing twelve months through Dec 2025 was $302.0 million (up 2.56% YoY), and the annual figure for FY2025 was $302.0 million, up 2.56%.
  • Shares Outstanding for Q4 2025 was $302.0 million at Pacific Biosciences Of California, roughly flat from $301.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding for PACB hit a ceiling of $302.0 million in Q4 2025 and a floor of $11.2 million in Q3 2021.
  • Median Shares Outstanding over the past 5 years was $254.4 million (2023), compared with a mean of $243.7 million.
  • Biggest five-year swings in Shares Outstanding: tumbled 93.77% in 2021 and later soared 1914.42% in 2022.
  • Pacific Biosciences Of California's Shares Outstanding stood at $221.0 million in 2021, then grew by 2.5% to $226.5 million in 2022, then grew by 18.21% to $267.7 million in 2023, then grew by 9.96% to $294.4 million in 2024, then increased by 2.56% to $302.0 million in 2025.
  • The last three reported values for Shares Outstanding were $302.0 million (Q4 2025), $301.9 million (Q3 2025), and $300.3 million (Q2 2025) per Business Quant data.